Craig Venter’s, Human Longevity, collaborating with Cleveland Clinic

Human Longevity, Inc (HLI) are a little closer to reaching their goal of sequencing and analyzing 1 million genomes by 2020. The California-based start-up, has entered into a broad collaborative agreement with Cleveland Clinic. HLI will sequence and analyze blood samples from the clinic’s GeneBank study of de-identified patients.

The collaborative effort aims to discover novel pathways, and novel genes, associated with heart disease.

“Cleveland Clinic is one of the premier clinical health care settings in the world and we are excited to be working with Dr. Cosgrove and his team. Using HLI’s powerful genomic technologies and analysis tools to better understand the biological basis for disease should enable earlier intervention and better treatments,” said J. Craig Venter, Ph.D., CEO of HLI.

“In medicine we are constantly exploring opportunities to better understand how diseases develop and what we can do to either prevent or provide the most impactful and effective course of treatment,” said Toby Cosgrove, M.D., President and CEO of Cleveland Clinic. “We are thrilled to be advancing the correlation of genomic data with clinical care.”

The GeneBank study got its start in 2000 as the brainchild of Dr Eric Topol during his tenure as chairman of cardiovascular medicine at Cleveland Clinic. Technology has advanced significantly since samples were collected in 2003. The collaboration with HLI is going to extend its relevance beyond what would have seemed possible a decade ago.

For HLI, this is another good move, keeping those HiSeq’s generating data. They received CLIA certification last month, and keep entering into high profile sequencing agreements. Where next for HLI? There’s a lot of sequencing and analysis to be done, but the odds must be pretty good that they’re going to find something very interesting in all that data- sooner rather than later.